mAbs
(Jan 2020)
Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
Feng Wang,
Jordan C. Tsai,
Jonathan H. Davis,
Bryant Chau,
Jia Dong,
Sean M. West,
Jason M. Hogan,
Matthew L. Wheeler,
Christine Bee,
Winse Morishige,
Thomas Cayton,
Donata David-brown,
Chengyue Zhang,
Alexander Kozhich,
Tim Sproul,
Gavin Dollinger,
Arvind Rajpal,
Pavel Strop
Affiliations
Feng Wang
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Jordan C. Tsai
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Jonathan H. Davis
Invenra, Inc, Madison, WI, USA
Bryant Chau
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Jia Dong
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Sean M. West
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Jason M. Hogan
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Matthew L. Wheeler
Immuno-Oncology Research, Bristol-Myers Squibb, Redwood City, CA, USA
Christine Bee
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Winse Morishige
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Thomas Cayton
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Donata David-brown
Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA
Chengyue Zhang
Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Redwood City, CA, USA
Alexander Kozhich
Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA
Tim Sproul
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Gavin Dollinger
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Arvind Rajpal
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
Pavel Strop
Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA
DOI
https://doi.org/10.1080/19420862.2019.1685350
Journal volume & issue
Vol. 12,
no. 1
Abstract
Read online
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of syngeneic mouse models requires the ability to generate surrogate mouse counterparts to antibodies designed for humans. In the field of bispecific antibodies, there remains a dearth of technologies available to generate native IgG-like mouse bispecific antibodies. Thus, we engineered a simple co-expression system for one-step purification of intact mouse IgG1 and IgG2a bispecific antibodies from any antibody pair. We demonstrated proof of concept with CD3/CD20 bispecific antibodies, which highlighted both the quality and efficacy of materials generated by this technology.
Keywords
Published in mAbs
ISSN
1942-0862 (Print)
1942-0870 (Online)
Publisher
Taylor & Francis Group
Country of publisher
United Kingdom
LCC subjects
Medicine: Therapeutics. Pharmacology
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website
https://www.tandfonline.com/journals/kmab
About the journal
WeChat QR code
Close